Immuron Limited researches, develops, and commercializes polyclonal antibodies in Australia,the United States, and internationally. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials.
